July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Switching from preserved prostaglandin therapy to preservative free tafluprost increases tear film thickness in patients with glaucoma
Author Affiliations & Notes
  • Anton B Hommer
    Ordination Dr. Hommer, Vienna, Austria
    Department of Clinical Pharmacology, Medical University Vienna , Vienna, Austria
  • Doreen Schmidl
    Department of Clinical Pharmacology, Medical University Vienna , Vienna, Austria
    Ordination Dr. Hommer, Vienna, Austria
  • Martina Kromus
    Ordination Dr. Hommer, Vienna, Austria
  • Ahmed M Bata
    Department of Clinical Pharmacology, Medical University Vienna , Vienna, Austria
  • Klemens Fondi
    Department of Clinical Pharmacology, Medical University Vienna , Vienna, Austria
  • Rene Marcel Werkmeister
    Center for Medical Physics and Biomedical Engineering, Medical University Vienna , Vienna, Austria
  • Carina Baar
    Department of Clinical Pharmacology, Medical University Vienna , Vienna, Austria
  • Leopold Schmetterer
    Department of Clinical Pharmacology, Medical University Vienna , Vienna, Austria
    Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore
  • Gerhard Garhofer
    Department of Clinical Pharmacology, Medical University Vienna , Vienna, Austria
  • Footnotes
    Commercial Relationships   Anton Hommer, Santen (F); Doreen Schmidl, None; Martina Kromus, None; Ahmed Bata, None; Klemens Fondi, None; Rene Werkmeister, None; Carina Baar, None; Leopold Schmetterer, None; Gerhard Garhofer, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1234. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anton B Hommer, Doreen Schmidl, Martina Kromus, Ahmed M Bata, Klemens Fondi, Rene Marcel Werkmeister, Carina Baar, Leopold Schmetterer, Gerhard Garhofer; Switching from preserved prostaglandin therapy to preservative free tafluprost increases tear film thickness in patients with glaucoma
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):1234.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is compelling evidence that chronic use of preservative-containing eye drops impacts ocular surface health. In the current study, we set out to investigate whether switching from topical preservative containing prostaglandin therapy to preservative-free tafluprost increases tear film thickness (TFT).

Methods : 30 patients under topical preservative-containing prostaglandin mono-therapy for at least 6 months were included in this study. Patients were then switched to preservative-free tafluprost eye drops once daily. TFT was measured before, 4 and 12 weeks after therapy change using a custom built ultra-high resolution optical coherence tomography (OCT) system. Furthermore, clinical parameters of ocular surface disease were determined.

Results : Switching to unpreserved tafluprost increased TFT from 4.7µm±0.5µm to 5.0µm±0.6µm 4 weeks after therapy change. After 12 weeks TFT still tended to be increased (4.8µm±0.7µm). Break up time (BUT) significantly increased from 5.1s±2.3s to 7.2s±3.4s and to 10.1s±3.6s after therapy change. In addition, a significant decrease in corneal staining score from 1.8±0.7 to 1.4±0.8 after 4 weeks and to 0.7±0.7 after 12 weeks of treatment was observed. Switching to preservative free drops reduced DEQS score from 11.4±11.0 to 5.7±6.4 and to 4.7±7.5.

Conclusions : Our data show that switching from preservative-containing glaucoma therapy to preservative-free tafluprost leads to an increase in TFT and to an amelioration of ocular surface disease related signs and symptoms. Our results therefore suggest that switching to unpreserved tafluprost therapy is beneficial for ocular surface health in patients under long-term preserved prostaglandin eye drops.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×